KRAS and non-small cell lung carcinoma: In NSCLC, KRAS mutations accounted for 93% of all RAS mutations, with KRASG12 mutations constituting 95% of all KRAS mutations.[24] This phenomenon underscored the pivotal role of KRASG12 mutation in the pathogenesis of NSCLC.